CINA-Aneurysm+
AVICENNA.AI · Decision date Oct 19, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for CINA-Aneurysm+ under 510(k) number K262147, with a decision date of 2026-10-19 and a receipt date of 06/25/2026. The applicant is Avicenna.Ai of La Ciotat, France. The device falls under regulation 892.2050, classification product code QIH, in the Radiology specialty and review panel. SESE in the 510(k) pathway denotes clearance for marketing, not premarket approval.
The submission is recorded as a Traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized Predetermined Change Control Plan. The public record does not describe the device's components, intended use, or the specific predicate it was compared against; those details would sit in the linked summary document, which was not available in the source text. No clinical performance or labeling conclusions are drawn here.
The page lists a last-updated date of 11/09/2026, which is metadata about the database entry rather than a regulatory action date.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Oct 19, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262147
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- AVICENNA.AI
- Product code
- QIH
- Decision code
- SESE
- Decision date
- Oct 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated Radiological Image Processing Software.
- Applicant
- Avicenna.AI
- Product code
- QIH
- FDA device class
- 2
FDA decision timeline
K262147 received
Application receipt date recorded by FDA.
K262147 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Clever OneK260372 | Ewoosoft Co., Ltd. | 510(k) clearance | Nov 4, 2026 | FDA |
PeekMed webK262667 | Peek Health, S.A. | 510(k) clearance | Nov 4, 2026 | FDA |
Ligence HeartK261733 | UAB Ligence | 510(k) clearance | Oct 7, 2026 | FDA |
NeuroDRK262134 | Deep Reasoning Ai, Inc. | 510(k) clearance | Oct 7, 2026 | FDA |
QGuideCT (1.0)K260523 | Medis Medical Imaging Systems BV | 510(k) clearance | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Avicenna.AI
- Headquarters
- Not reported
- Brand website
- avicenna.ai
- FDA applicant address
- La Ciotat
Sources and methodology
- Original FDA record: K262147
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

